Source ID: C16
Original URL: https://www.astrazeneca.com/content/dam/az/PDF/2026/h1q2/H1-and-Q2-2026-results-clinical-trials-appendix.pdf
Source date (attachment preserved): 2026-07-27
Data date (attachment preserved): 2026-07-27
Checked at: 2026-10-07T18:42:25+08:00
Timezone: Asia/Taipei
Retrieval mode: public_url_web_tool
Read level: 154頁公司公開 PDF，只核 ADC 必要試驗列：印刷第15–16頁（PDF index14–15）及日期；未分析全份
Access result: 正常取得原 URL PDF 文字；未保存或聲稱下載全 PDF
Original raw artifact SHA256: null

LOCATORS (actual reading positions):
封面 H1 2026 Results Update / 27 July 2026，L0–2
印刷第15頁，TROPION-Breast03，L850–866
印刷第16頁：AVANZAR L909–919；TROPION-Lung07 L921–936；Lung08 L938–952；Lung15 L989–1006

MINIMUM VERBATIM EXCERPT (only this block is source prose):
Data anticipated: H1 2027

EXTRACTED FACTUAL FIELDS (not a reconstructed quotation):
[
  {
    "trial": "AVANZAR",
    "locator": "印刷p16 L909–919",
    "date_guidance": "H2 2026",
    "kind": "company anticipated data",
    "population": "1L 局部晚期/轉移 NSCLC，無可作用基因改變"
  },
  {
    "trial": "TROPION-Lung15",
    "locator": "印刷p16 L989–1006",
    "date_guidance": "H2 2026",
    "kind": "company anticipated data",
    "population": "2L EGFRm NSCLC，先前 Tagrisso 後進展"
  },
  {
    "trial": "TROPION-Lung07",
    "locator": "印刷p16 L921–936",
    "date_guidance": "H1 2027",
    "kind": "company anticipated data",
    "population": "1L PD-L1 TC <50% NSCLC，無可作用基因改變"
  },
  {
    "trial": "TROPION-Lung08",
    "locator": "印刷p16 L938–952",
    "date_guidance": "H1 2027",
    "kind": "company anticipated data",
    "population": "1L PD-L1 TC >=50% 非鱗狀 NSCLC，無可作用基因改變"
  },
  {
    "trial": "TROPION-Breast03",
    "locator": "印刷p15 L850–866",
    "date_guidance": "H2 2027",
    "kind": "company anticipated data",
    "population": "術前治療後未達 pCR 的 I–III 期 TNBC"
  }
]

SCOPE / PRECISE GAP (reviewer description, not source prose):
現版直接支持五項 anticipated data 時窗；不能單憑本版證明 Lung07 曾從舊 H2 2026 改期。未查其他年份原始版本，建議僅刪舊版比較子句。

Web refs: turn116view4, turn118view2, turn118view4, turn133view3, turn134view0